Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines
- PMID: 8912845
Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines
Abstract
Loss of heterozygosity at the short arm of chromosome 3 occurs frequently in head and neck squamous cell carcinoma (HNSCC). FHIT, a candidate tumor suppressor gene, was recently identified at 3p14.2, and abnormalities of the gene were found in several types of human cancers. To investigate a potential role of the FHIT gene in HNSCC, we examined 16 HNSCC cell lines from 11 patients for abnormalities of the gene by using microsatellite analysis, reverse transcription-PCR, sequencing, and Southern blot analysis. We found that 13 of 16 (81%) cell lines exhibit loss of heterozygosity at 3p14.2. Seven cell lines from six individuals exhibited abnormal transcription patterns, including lack of a FHIT transcript in three lines and shortened transcripts in four lines. A further examination of coding sequences of FHIT in all lines with FHIT transcripts revealed a deletion of exon 4 in one line, a deletion of exons 5 to 7 in one line, and a deletion of exons 5 to 7 plus multiple small insertions between exons 4 and 8 in two lines derived from a primary tumor and a metastasis in the same individual. These results indicate that FHIT may have been inactivated in six cell lines from five (45%) individuals. We also observed two common polymorphism sites at codons 88 and 98 of the gene. These data indicate that abnormal transcription of the FHIT gene is common in HNSCC cell lines; however, other tumor suppressor gene(s) may reside at the same chromosomal region.
Similar articles
-
FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.Cancer Res. 1997 Jun 1;57(11):2256-67. Cancer Res. 1997. PMID: 9187130
-
Analysis of the FHIT gene and its product in squamous cell carcinomas of the head and neck.Oncogene. 1998 Jul 9;17(1):83-91. doi: 10.1038/sj.onc.1201910. Oncogene. 1998. PMID: 9671317
-
Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.Cancer Res. 1997 Sep 1;57(17):3664-8. Cancer Res. 1997. PMID: 9288768
-
The Fragile Histidine Triad gene and breast cancer.Med Sci Monit. 2002 Jul;8(7):RA140-4. Med Sci Monit. 2002. PMID: 12118213 Review.
-
The role of the FHIT/FRA3B locus in cancer.Annu Rev Genet. 1998;32:7-31. doi: 10.1146/annurev.genet.32.1.7. Annu Rev Genet. 1998. PMID: 9928473 Review.
Cited by
-
Effect of regulated expression of the fragile histidine triad gene on cell cycle and proliferation.Mol Cell Biochem. 2000 Jan;204(1-2):83-8. doi: 10.1023/a:1007068823848. Mol Cell Biochem. 2000. PMID: 10718628
-
Purification and crystallization of complexes modeling the active state of the fragile histidine triad protein.Protein Eng. 1997 Dec;10(12):1461-3. doi: 10.1093/protein/10.12.1461. Protein Eng. 1997. PMID: 9543008 Free PMC article.
-
Analysis of loss of heterozygosity in Korean patients with keratoacanthoma.J Korean Med Sci. 2005 Apr;20(2):340-3. doi: 10.3346/jkms.2005.20.2.340. J Korean Med Sci. 2005. PMID: 15832014 Free PMC article.
-
Replacement of Fhit in cancer cells suppresses tumorigenicity.Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13771-6. doi: 10.1073/pnas.94.25.13771. Proc Natl Acad Sci U S A. 1997. PMID: 9391102 Free PMC article.
-
Integrated analysis of FHIT gene alterations in cancer.Cell Cycle. 2024 Jan;23(1):92-113. doi: 10.1080/15384101.2024.2304509. Epub 2024 Jan 18. Cell Cycle. 2024. PMID: 38234243 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical